Bigbear Pharmaceutical·Medication Guide

• What if I miss a dose?

  Take the missed dose as soon as possible; however, if less than 6 hours have passed since the next dose, skip the missed dose. Never take a double dos···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 91

• The FDA approved the combination of encorafenib and binimetinib

  On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination of encorafenib and binimetinib for the treatment of patients wi···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 92

• Binimetinib (Mektovi) Patient Guide: Uses, Dosage, and What to Expect

  Binimetinib, developed by Pierre Fabre in France, was approved by the U.S. Food and Drug Administration (FDA) in 2018, providing a new treatment optio···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 91

• Binimetinib Dosage and Administration: Common Dosage and Dosage Adjustment

  Binimetinib is often used in combination with encorafenib. These two drugs target the same signaling pathway at different points and can synergistical···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 87

• Side effects and adverse reactions of Binimetinib

  While binimetinib offers a new treatment option for melanoma patients, its potential adverse reactions still require careful monitoring during use.Sid···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 87

• Anagrelide detailed instructions: indications, dosage, side effects, and precautions

  Anagrelide is a platelet-reducing agent, also known as a platelet production inhibitor. Domestically produced Anagrelide capsules were launched in Chi···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 95

• Anagrelide Dosage and Administration: Standard Dosage, Dosage Adjustment

  Anagrelide is a selective platelet-producing inhibitor, approved for marketing in the United States in 1997, and subsequently approved in Europe and o···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 94

• Side effects and adverse reactions of Anagrelide

  Anagrelide is primarily used to treat thrombocytosis, especially essential thrombocytosis, reducing the risk of thrombosis and improving patients'···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 95

• Detailed information on the targeted drug Braftovi (Entofen)

  Braftovi is a targeted therapy specifically for BRAF V600E gene mutations. It is often used in combination with other drugs (such as cetuximab and bim···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 93

• instruction manual for the targeted drug Encorafenib

  Encorafenib is an oral small-molecule BRAF kinase inhibitor developed and manufactured by Pierre Fabre in France. It received marketing approval from ···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 87

• Encorafenib side effects: serious adverse reactions, common side effects, side effect management

  Encorafenib is an oral small-molecule BRAF kinase inhibitor developed and manufactured by Pierre Fabre in France. In 2018, encorafenib received market···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 97

• Encorafenib (Braftovi) Patient Guide: Uses, Side Effects, and What to Expect

  Encorafenib exerts its anti-tumor effect by specifically inhibiting the activity of BRAF mutant protein, thereby blocking tumor cell proliferation and···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 97

• FDA-approved indications and approval history for each indication of Encorafenib

  Since its initial FDA approval in 2018 for the treatment of melanoma, encorafenib has continued to expand its indications, bringing new treatment opti···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 98

• The FDA has approved sotorarazib (Lumakras) in combination with panitumumab

  Here is the professional, accurate English translation of the full text, formatted for medical/pharmaceutical documentation:On May 28, 2021, Amgen ann···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 97

• The FDA has approved sotorarazib (Lumakras) in combination with panitumumab

  On January 17, 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the combination of sottorazib (Lumakras) and panitu···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 97